csirt@kutim:~/threat-intel/cve/CVE-2026-18322

Katalog CVE

CVSS 8.8 · High EPSS 0,59%

Kerentanan Improper Privilege Management. Skor CVSS 3.1 8.8 (High) menurut wordfence.com.

Deskripsi (NVD)

The Smart Popup by Supsystic plugin for WordPress is vulnerable to Privilege Escalation in all versions up to, and including, 1.12.0. This is due to a permission map collision in the `havePermissions()` function in `classes/frame.php`, where `array_merge()` overwrites the popup module's administrator-restricted method list with the base controller's value, silently removing `save` from protected actions; this is compounded by the subscription confirmation email embedding the same generic `pps_nonce` that the unauthenticated `wp_ajax_nopriv_save` endpoint accepts, and by the complete absence of any server-side role allowlist in `createWpSubscriber()`. This makes it possible for unauthenticated attackers to submit a crafted POST request to `admin-ajax.php` using a nonce obtained from a public subscription confirmation email, setting `params[tpl][sub_wp_create_user_role]` to `administrator` via the exposed `popupControllerPps::save()` action, and then triggering the stored confirmation flow to create a persistent WordPress Administrator account with attacker-chosen credentials.

Rincian

Terbit di NVD
5 Agustus 2026
Terakhir diubah
12 Agustus 2026
Status NVD
Deferred
CVSS 3.1
8.8 (High), sumber wordfence.com
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-269: Improper Privilege Management
EPSS (30 hari)
0,59% peluang dieksploitasi; lebih tinggi dari 46,6% CVE lain

Produk dan versi terdampak

NVD belum mencantumkan data produk (CPE) untuk CVE ini. Produk yang terdampak biasanya disebut di deskripsi dan di advisory vendor pada daftar referensi.

Referensi dan perbaikan

Sumber: NVD · CVE.org · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.